Communiqués ZyVersa Therapeutics, Inc.

Actions

ZVSA

US98987D3008

Recherche biotechnologique et médicale

Temps réel OTC Markets Autres places de cotation 17:39:02 04/06/2026			Varia. 5j.	Varia. 1 janv.
0,1800 ^USD	+5,88%		+50,00%	+34,73%

10/07	Zyversa Therapeutics, Inc. annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 8 juillet 2026	CI
13/05	ZyVersa Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

13/05	ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
31/03	ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update	AQ
19/11	ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results	AQ
10/09/25	ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes	AQ
03/09/25	ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression	AQ
14/08/25	ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression	AQ
13/08/25	ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones	AQ
21/07/25	ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress	AQ
08/07/25	ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds	AQ
08/07/25	ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis	AQ
26/06/25	ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)	AQ
25/06/25	ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200	AQ
20/05/25	ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases	AQ
12/05/25	ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress	AQ
07/05/25	ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update	AQ
29/04/25	ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease	AQ
08/04/25	ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)	AQ
27/03/25	ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update	AQ
18/03/25	ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study	AQ
12/03/25	ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model	AQ
06/03/25	ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market	AQ
05/03/25	ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes	AQ
18/12/24	ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco	AQ
20/11/24	ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial	AQ
14/11/24	ZyVersa Therapeutics : Reports Third Quarter, 2024 Financial Results and Provides Business Update Form 8 K	PU